SANA Sana Biotechnology, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SANA matters now
Sana Biotechnology, Inc. (SANA) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.85 with -2.04% on the session and $1.07B in market capitalization; recent performance reads 1-month +2.94% and YTD -22.60%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-47.2M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.2%.
The latest indexable market news headline is "Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.00; recent insider activity includes NELSEN ROBERT filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.31
P/S
0.00
EV/EBITDA
-4.64
DCF Value
$-0.03
FCF Yield
-15.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-161.9%
ROA
-64.8%
ROIC
-78.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-47.2M | $-0.17 |
| Q4 2025 | $0.00 | $-58.8M | $-0.20 |
| FY 2025 | $0.00 | $-244.2M | $-0.96 |
| Q3 2025 | $0.00 | $-42.2M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.67
Target (Median)
$7.00
Target Range
$7.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.16
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.